Spreadsheet: 27cec131-a7ec-4a2c-933a-0449ddd24469
Sheet: TableS6

Table S6 - Meta-analyses of pharmacogenomics studies related to infectious diseases, 2001–2010.
Reference | Phenotype | Gene | # Studies | Contrast | # Persons | # Events | Effect size* | Hetero- geneity§
Alfirevic A, 2003 | SMX hypersensitivity | NAT2 | 4 | NR | NR | NR | 2.25 (0.45-11.2) | NR
Sun F, 2008 | anti-TB drug-induced hepatotoxicity | CYP2E1 | 5 | CYP2E1*1A/*1A vs. others | 701 | 176 | 2.22 (1.06-4.66) | 0.06
 |  | GSTM1 | 5 | GSTM1 null/[NAME] vs. null/+ & +/+ | 192 | 96 | 2.62 (1.45-4.75) | NS
 |  | GSTT1 | 5 | GSTT1 null/null vs. null/+ & +/+ | 192 | 96 | 1.18 (0.61-2.29) | NS
 |  | NAT2 | 5 | NAT2 mt/mt vs. w/mt and w/w | 625 526 | 133 99 | all: 1.93 (0.81-4.62) Asian: 2.52 (1.49-4.26) | 0.03 NS
[NAME], 2006 | proton pump inhibitor-related  H. pylori eradication | CYP2C19 | 17 | HomEM vs. [NAME]        all therapies combined      omeprazole       lansoprazole      rabeprazole  HomEM vs. HetEM      all therapies combined      omeprazole       lansoprazole      rabeprazole  HetEM vs. PM      all therapies combined      omeprazole       lansoprazole       rabeprazole | HomEM vs. PM    1168    430    169    324 HomEM vs. HetEM     1,807     N/A     N/A     N/A HetEM vs. PM     1321     N/A     N/A     N/A | HomEM vs. PM    889    303    132    203 HomEM vs. HetEM     1,396     N/A     N/A     N/A HetEM vs. PM     1113     N/A     N/A      N/A | HomEM vs. PM    2.70 (1.46-4.98)    4.03 (1.97-8.28)    1.80 (0.67-4.85)    1.04 (0.44-2.46) HomEM vs. HetEM    1.90 (1.38-2.60)    2.12 (1.38-3.25)    1.59 (0.87-2.88)    1.71 (0.93-3.13) HetEM vs. PM    1.36 (0.89-2.07)    2.24 (1.09-4.61)    0.73 (0.28-1.88)    0.66 (0.36-1.23) | >0.05
[NAME], 2008 | proton pump inhibitor-related  H. pylori eradication | CYP2C19 | 20 | HomEM vs. [NAME]        all therapies combined      omeprazole       lansoprazole      rabeprazole  HomEM vs. HetEM      all therapies combined      omeprazole       lansoprazole      rabeprazole  HetEM vs. PM      all therapies combined      omeprazole       lansoprazole       rabeprazole | HomEM vs. PM‡    1735    HomEM vs. [NAME]    2815    HetEM vs. PM    2034 | HomEM vs. PM‡    1383    HomEM vs. HetEM     2248    HetEM vs. PM    1771 | HomEM vs. PM    2.79 (1.77-4.41)    4.28 (1.88-9.74)    3.06 (1.56-6.00)    1.35 (0.42-4.32) HomEM vs. [NAME] (1.47-2.71)    3.22 (1.91-5.42)    1.95 (1.03-3.70)    1.04 (0.54-2.00) HetEM vs. PM    1.73 (1.23-2.44)    1.43 (0.60-3.63)    1.62 (0.82-3.20)    1.57 (0.84-2.94) | NR
[NAME], 2010 | Antiretroviral therapy-related lipodystrophy syndrome in HIV-1-infected patients | TNFα | 3 | TNFα -238  GG vs. GA + AA TNFα -238 A allele vs. non TNFα -308  GG vs. GA + AA TNFα -308 A allele vs. non | 258 258  265 265 | 305 305 301 301 | 1.41 (0.82-2.42) 1.40 (0.84-2.35) 0.82 (0.42-1.62) 0.83 (0.58-1.19) | NS
*Risk Ratio unless otherwise noted
°The authors looked at two subgroups: seroconverters (shown on top) and seroprevalent patients (shown below); [NAME] shown, for time until AIDS diagnosis
§ Heterogeneity not significant (NS), not reported (NR), or significant (value reported)
†Strata represent dual or triple therapies comprising one PPI (omeprazole, lansoprazole, or rabeprazole) combined with one or two antibiotics; HomEM = *1/*1, HetEM = *1/*2 or *1/*3,   PM = *2/*2, *1/*2 and *1/*3, or *3/*3; *3 refers to mutation on [NAME], *2 refers to mutation on exon5
‡Sample sizes reported for all triple therapies combined
§§Heterogeneity not reported for individual therapy subset analyses, expect rabeprazole: HomEM vs. PM (p=0.61), HomEM vs. HetEM (p=0.91), HetEM vs. PM (p=0.19)